Myopia is a rapidly growing significant public health concern, affecting one-third of the US adults and up to 80-90% of the population in some East Asian countries. Even low myopia carries substantial risks of developing sight-threatening ocular pathologies like myopic maculopathy, which is already the leading cause of new blindness in regions where myopia is highly prevalent. Developing effective strategies to control is an urgent priority need. Our lab is using the knowledge gained from animal models to investigate the safety and efficacy of novel interventions to control myopia in children.

  1. Khanal S, Phillips JR. Is Recommending 0.01% Atropine for Myopia Control Clinically Meaningful? JAMA Ophthalmol. Published online February 15, 2024.
  2. Khanal S, Phillips JR. Which low-dose atropine for myopia control? Clin Exp Optom. 2020 Mar;103(2):230-232. PMID: 31489714; PMCID: PMC7065125.
  3. Khanal S. Is myopia a disease or just a dis-ease? Ophthalmic Physiol Opt. 2023 Jul;43(4):595-597. Epub 2023 Apr 17. PMID: 37069742.
  4. Logan NS, Radhakrishnan H, Cruickshank FE, Allen PM, Bandela PK, Davies LN, Hasebe S, Khanal S, Schmid KL, Vera-Diaz FA, Wolffsohn JS. IMI Accommodation and Binocular Vision in Myopia Development and Progression. Invest Ophthalmol Vis Sci. 2021 Apr 28;62(5):4.